IR Information
To ensure sustainable growth for the next 100 years
Div per Share
Div and Yield
Based on principles of transparency, fairness, and continuity, we work to
promptly disclose company information to the public.
- Net Sales
- 400.3 B JPY
- Operating
Income - 14.4 B JPY
- Net Income
- -12.3 B JPY
- Total Assets
- 655.5 B JPY
- Equity Ratio
- 45.2 %
- Dividends per Share
- 100 JPY
- ROE
- -4.1 %
Related Links
IR Topics
- 2026/3/11 Summary of Q&A Session for Management Presentation on Feb 27 2025
- 2026/3/9 Notice Concerning Change in Equity-Method Affiliate (Becoming a Consolidated Subsidiary)
- 2026/3/5 Presentation Materials for Management Presentation on Feb 27 2026 with Script
- 2026/3/5 (Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)” and Public Notice of Commencementof Tender Offer Dueto Filingof Amendment Statement
- 2026/2/27 Notice of Formulation of Management Plan “Mission 2030” Phase 2 (FY2026–FY2028)
About use of IR information
About use of IR information
The investor relations (IR) information on this website is presented in order to provide financial information,
management indicators, and other data on Denka Company Limited. The company does not make no representation or
warranties with regard to the content.
The IR information on this website does not constitute a solicitation of investment. In actual decisions on
investment, investors are asked to refrain from depending entirely on this information and to make decisions
based on their own independent examinations and judgments.
About future outlook
Some of the information presented on this website includes statements about expected future performance. These statements do not guarantee any future result; and they contain factors of risk and uncertainty. Please note that actual future results could possibly differ from this future outlook, owing to changes in the environment and other circumstances.
